



Hemogenyx Pharma Plc - Directorate Change

12/20/2018

RNS Number : 0371L

Hemogenyx Pharmaceuticals PLC

20 December 2018

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

Directorate Change

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that Robin Campbell, Non-Executive Director, will step down from the Board with effect from 5 January 2019.

Dr Campbell became a Director of Hemogenyx in October 2017 and was Chairman during the Company's listing on the Main Market of the London Stock Exchange. In April 2018 Robin became Non-Executive Director.

Sir Marc Feldmann, Executive Chairman of Hemogenyx, commented:

"I would like to thank Robin for his contribution to the Company, especially during the listing, and for his support as both Chairman and Non-Executive Director. We wish him well in his future

endeavors."

The Company expects to announce a replacement Board appointment in the near future.

Enquiries:

Hemogenyx Pharmaceuticals Plc
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

www.hemogenyx.com
Via Walbrook PR

Sir Marc Feldmann, Executive Chairman

Northland Capital Partners Limited
Matthew Johnson, Vadim Alexandre, Dugald J Carlean

Tel: +44 (0)20 3861 6625

Peterhouse Corporate Finance Limited
Lucy Williams, Duncan Vasey

Tel: +44 (0)20 7469 0930

Walbrook PR (UK Media & Investor Relations)
Paul McManus

Tel: +44 (0)20 7933 8780 or **hemogenyx@walbrookpr.com**
Mob: +44 (0)7980 541 893

US Media enquiries
Lowell Goodman

Tel: +1 (323) 646-3249 or **lowell@corbomitecomms.com**

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, Hemogenyx LLC, located in Brooklyn, New York at its state-of-the-art research facility.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END



BOAGGGAGPUPRGMB

